Skip to content
Peptigraph home

ZUPREME: Petrelintide Phase 2 trial (NCT06662539)

A Randomized, Double-blind, Phase 2, Dose-finding Trial of Once Weekly Petrelintide Compared With Placebo in Participants With Obesity or Overweight With Weight Related Comorbidities

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
493
actual
Start
9 Dec 2024 (actual)
Primary completion
30 Sep 2025 (actual)
Sponsor
Zealand Pharma
Design

Arms and doses

NCT06662539 study arms
ArmTypeInterventionsDescription
Petrelintide Dose 1ExperimentalDrug: PetrelintideParticipants will self-inject petrelintide dose 1 subcutaneously once a week.
Petrelintide Dose 2ExperimentalDrug: PetrelintideParticipants will self-inject petrelintide dose 2 subcutaneously once a week.
Petrelintide Dose 3ExperimentalDrug: PetrelintideParticipants will self-inject petrelintide dose 3 subcutaneously once a week.
Petrelintide Dose 4ExperimentalDrug: PetrelintideParticipants will self-inject petrelintide dose 4 subcutaneously once a week.
Petrelintide Dose 5ExperimentalDrug: PetrelintideParticipants will self-inject petrelintide dose 5 subcutaneously once a week.
PlaceboPlacebo comparatorDrug: PlaceboParticipants will self-inject matching placebo to petrelintide subcutaneously once a week.
Endpoints

Primary endpoint

NCT06662539 primary outcomes
MeasureTime frame
Percent change from baseline in body weight to Week 28From Baseline (Day 1) to Week 28
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT06662539 secondary outcomes
MeasureTime frame
Percentage of Participants achieving ≥5% Body Weight Loss at Weeks 28 and 42From Baseline (Day 1) to Weeks 28 and 42
Percentage of Participants achieving ≥10% Body Weight Loss at Weeks 28 and 42From Baseline (Day 1) to Weeks 28 and 42
Change from baseline in body weight to Weeks 28 and 42From Baseline (Day 1) to Weeks 28 and 42
Change from baseline in waist circumference to Weeks 28 and 42From Baseline (Day 1) to Weeks 28 and 42
Percent change from baseline in body weight to Week 42From Baseline (Day 1) to Week 42
Change from baseline in hemoglobin A1c (HbA1c) to Week 42From Baseline (Day 1) to Week 42
Change from baseline in fasting glucose to Week 42From Baseline (Day 1) to Week 42
Change from baseline in high-sensitivity C-reactive protein (hsCRP) to Week 42From Baseline (Day 1) to Week 42
Change from baseline in fasting lipids to Week 42From Baseline (Day 1) to Week 42
Number of treatment emergent adverse events (TEAEs)From Baseline (Day 1) to Week 51
Occurrences of anti-drug antibodies (ADAs) to petrelintideFrom Baseline (Day 1) to Week 51
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Randomized, Double-blind, Phase 2, Dose-finding Trial of Once Weekly Petrelintide Compared With Placebo in Participants With Obesity or Overweight With Weight Related ComorbiditiesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.